We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+0.31%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$2.95B
AUM Growth
-$162M
Cap. Flow
+$94.6M
Cap. Flow %
3.21%
Top 10 Hldgs %
48.26%
Holding
91
New
14
Increased
7
Reduced
3
Closed
6

Top Buys

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$46.4M
2
CGEM icon
Cullinan Oncology
CGEM
+$43.6M
3
NUVB icon
Nuvation Bio
NUVB
+$39.6M
4
CNTB
Connect Biopharma Holdings
CNTB
+$35.4M
5
IMVT icon
Immunovant
IMVT
+$26.4M

Top Sells

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$116M
2
PAND
Pandion Therapeutics Inc. Common Stock
PAND
+$31.3M
3
PRVL
Prevail Therapeutics Inc. Common Stock
PRVL
+$25.9M
4
LABD icon
Direxion Daily S&P Biotech Bear 3X ETF
LABD
+$19.4M
5
CLDX icon
Celldex Therapeutics
CLDX
+$17.5M

Sector Composition

Rank Sector Weight
1 Healthcare 96.52%
2 Financials 0.94%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LJPC
76
DELISTED
La Jolla Pharmaceutical Company
LJPC
$3.78M 0.13%
890,700
– –
TARA icon
77
Protara Therapeutics
TARA
$220M
$3.29M 0.11%
209,227
– –
GNCA
78
DELISTED
Genocea Biosciences, Inc.
GNCA
$3.07M 0.1%
1,134,453
– –
SNCE
79
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$2.03M 0.07%
10,000
– –
OMEG
80
DELISTED
Omega Alpha SPAC Class A Ordinary Shares
OMEG
$1.98M 0.07%
+200,000
New +$2.08M
CHFW.U
81
DELISTED
Consonance-HFW Acquisition Corp. Units, each consisting of one Class A Ordinary Share, and one-third
CHFW.U
$1.95M 0.07%
200,000
– –
BOLT icon
82
Bolt Biotherapeutics
BOLT
$7.67M
$1.65M 0.06%
+2,500
New +$1.63M
CLRB icon
83
Cellectar Biosciences
CLRB
$20.5M
$1.48M 0.05%
3,067
– –
NUVB.WS
84
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$712K 0.02%
+266,666
New +$771K
ZGNX
85
DELISTED
Zogenix, Inc.
ZGNX
$533K 0.02%
27,300
– –
CLDX icon
86
Celldex Therapeutics
CLDX
$2.99B
– –
-1,000,000
Closed -$17.5M
VINC
87
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
– –
-15,000
Closed -$6.27M
SPPI
88
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
– –
-3,333,333
Closed -$11.4M
PAND
89
DELISTED
Pandion Therapeutics Inc. Common Stock
PAND
– –
-2,107,513
Closed -$31.3M
FSDC
90
DELISTED
FS Development Corp. Class A Common Stock
FSDC
– –
-700,000
Closed -$7.7M
PRVL
91
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
– –
-1,123,105
Closed -$25.9M
1 2 3
4

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q1 2021 Portfolio in Review

As of Q1 2021, Boxer Capital held 91 positions worth $2.95B, down 5.2% from $3.11B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Boxer Capital deployed $94.6M of net new capital in Q1 2021, opening 14 new positions and adding to 7 existing holdings. Its largest new stake was Cullinan Oncology: 1,074,082 shares worth $44.8M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 97% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was BeOne Medicines Ltd, an estimated $116M trimmed.

  • Boxer Capital's largest Q1 2021 buy was Cullinan Oncology: 1,074,082 shares worth $44.8M.
  • Boxer Capital added most to Mirati Therapeutics, Inc. Common Stock in Q1 2021, an estimated $46.4M increase.
  • Boxer Capital's biggest Q1 2021 reduction was BeOne Medicines Ltd, cutting an estimated $116M.
  • Boxer Capital fully exited Pandion Therapeutics Inc. Common Stock in Q1 2021, selling an estimated $31.3M.
  • Boxer Capital's ten largest holdings make up 48% of its $2.95B portfolio in Q1 2021.
  • Boxer Capital opened 14 new positions and closed 6 in Q1 2021.
  • Boxer Capital's portfolio value fell 5.2% quarter-over-quarter to $2.95B.

Based on Boxer Capital's 13F filing for Q1 2021, filed 17 May 2021.